Investor
venBio Partners LLC
CIK 0001776382 · filed 2026-05-15 · SEC filing
13F book
$280.6M
Positions
6
Largest name
46.7%
Pharvaris N.V. · PHVS
Est. mark
$59.3M
Price effect on 6 names still held. Flow $4.99M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Pharvaris N.V. | PHVS | 4.64M | $131.1M | 46.7% | $2.32M | Held |
| Alumis Inc. | ALMS | 4.53M | $99.8M | 35.6% | $55.6M | Cut$54.7M |
| Alx Oncology Hldgs Inc | — | 12.9M | $25.8M | 9.2% | $8.49M | Added$14.9M |
| Harmony Biosciences Hldgs In | — | 489.2K | $13.7M | 4.9% | −$4.6M | Held |
| Lyell Immunopharma, Inc. | LYEL | 337.7K | $6.77M | 2.4% | −$3.62M | Held |
| Artiva Biotherapeutics, Inc. | ARTV | 531.3K | $3.42M | 1.2% | $1.14M | Cut$639.7K |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.